Quoin Pharmaceuticals Ltd ADR (QNRX) concluded trading on Wednesday at a closing price of $0.29, with 207.74 million shares of worth about $60.24 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.67% during that period and on April 03, 2025 the price saw a gain of about 38.23%. Currently the company’s common shares owned by public are about 8.95M shares, out of which, 5.03M shares are available for trading.
Stock saw a price change of -0.85% in past 5 days and over the past one month there was a price change of -0.85%. Year-to-date (YTD), QNRX shares are showing a performance of -55.05% which decreased to -68.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.21 but also hit the highest price of $1.57 during that period. The average intraday trading volume for Quoin Pharmaceuticals Ltd ADR shares is 5.38 million. The stock is currently trading 2.38% above its 20-day simple moving average (SMA20), while that difference is down -6.26% for SMA50 and it goes to -46.62% lower than SMA200.
Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) currently have 8.95M outstanding shares and institutions hold larger chunk of about 17.28% of that.
The stock has a current market capitalization of $2.62M and its 3Y-monthly beta is at 1.39. It has posted earnings per share of -$2.34 in the same period. It has Quick Ratio of 3.57 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for QNRX, volatility over the week remained 24.47% while standing at 11.52% over the month.
Analysts are in expectations that Quoin Pharmaceuticals Ltd ADR (QNRX) stock would likely to be making an EPS of -0.12 in the current quarter, while forecast for next quarter EPS is -0.13 and it is -0.35 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.12 which is -0.12 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 33.51% while it is estimated to increase by 68.50% in next year.
